No incidence of BRAF mutations in salivary gland carcinomasImplications for anti-EGFR Therapies

Journal of Biomedicine and Biotechnology

Volumn 2009, Issue , 2009, Pages

  Dahse, Regine ^a   Kromeyer Hauschild, Katrin ^b   Berndt, Alexander ^b   Kosmehl, Hartwig ^a  

^a HELIOS KLINIKUM ERFURT   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SALIVARY GLAND CARCINOMA; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; POINT MUTATION; SALIVARY GLAND TUMOR; SIGNAL TRANSDUCTION;

ALLELES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 68149150990     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2009/501736     Document Type: Article

References (13)

1. Milano A., Longo F., Basile M., Iaffaioli R. V., Caponigro F., Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy Oral Oncology 2007 43 8 729 734
2. Dahse R., Driemel O., Schwarz S., Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas British Journal of Cancer 2009 100 4 623 625
3. Dahse R., Driemel O., Schwarz S., Kromeyer-Hauschild K., Berndt A., Kosmehl H., KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncology. In press
4. Davies H., Bignell G. R., Cox C., Mutations of the BRAF gene in human cancer Nature 2002 417 6892 949 954
5. Di Nicolantonio F., Martini M., Molinari F., Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer Journal of Clinical Oncology 2008 26 35 5705 5712
6. Barnes L., Eveson W., Reichart P., Sidransky W., Pathology and genetics of head and neck tumours World Health Organization Classification of Tumours 2005 Lyon, France IARC Press 210 242
7. Locati L. D., Bossi P., Perrone F., Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncology. In press
8. Glisson B. S., Blumenschein G., Francisco M., Erasmus J., Zinner R., Kies M., Phase II trial of gefitinib in patients with incurable salivary gland cancer Journal of Clinical Oncology 2005 23 16S 5532
9. Agulnik M., Cohen E. W. E., Cohen R. B., Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands Journal of Clinical Oncology 2007 25 25 3978 3984
10. Jhawer M., Goel S., Wilson A. J., PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Research 2008 68 6 1953 1961
11. Sartore-Bianchi A., Martini M., Molinari F., PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Research 2009 69 5 1851 1857
12. Sarkar G., Cassady J., Bottema C. D. K., Sommer S. S., Characterization of polymerase chain reaction amplification of specific alleles Analytical Biochemistry 1990 186 1 64 68
13. Newton C. R., Graham A., Heptinstall L. E., Analysis of any point mutation in DNA. The amplification refractory mutation system [ARMS] Nucleic Acids Research 1989 17 2503 2516